Healthcare AI startup Harrison.ai has raised A$129 million ($97 million) in a Series B funding round and teamed up with listed medical diagnostics provider Sonic Healthcare to create new AI tools in pathology.
WHAT IT DOES
Founded in 2018, Harrison.ai is known for its flagship product Annalise CXR, an AI-based clinical decision support tool that reads chest x-rays. The device detects 124 findings and is based on over 520,000 chest x-ray studies which comprise more than 820,000 individual images. It co-developed and marketed the tool with I-MED Radiology early last year. Aside from pathology, it has created AI tech in IVF with Virtus Health.
WHAT IT’S FOR
According to a press release, the latest funds will be used to expand the company’s team of AI data scientists and engineers, while entering new markets with global partners.
Meanwhile, it has partnered with Sonic Healthcare to “rapidly” commercialise new AI pathology solutions as it intends to help in closing the gap in pathology skills shortage globally.
THE LARGER TREND
Diagnostic imaging provider Sonic Imaging has recently deployed Annalise CXR across its 100 radiology clinics. About 350 Australian radiologists have been using the device to date, according to Harrison.ai.
ON THE RECORD
“Delivering equitable, effective and accurate healthcare to more people is a critical part of our mission at Harrison.ai and as we emerge from the pandemic that mission is more important than ever. With our model and methodology now proven across multiple clinical areas, we are in a position to expand to new clinical areas and deliver on our mission with the support of our investors and partners,” said Dr Aengus Tran, co-Founder and CEO of Harrison.ai.